NAP Peptide (NAPVSIPQ)

Microtubule Dynamics and EB1/EB3 Interaction

Oz et al. identified the SxIP motif within NAP as the molecular basis for its microtubule interaction. NAP binds EB1 and EB3 at microtubule plus-ends, promoting polymerization and reducing catastrophe frequency. This interaction is critical for maintaining axonal transport of mitochondria, synaptic vesicles, and neurotrophic factor receptors. Disruption of microtubule dynamics is a common pathological feature across neurodegenerative diseases, making NAP's mechanism broadly relevant. Oz S. et al. (2014) -- J. Biol. Chem.

Tau Pathology Protection

Vulih-Shultzman et al. showed that NAP protects against tau hyperphosphorylation and aggregation in multiple model systems. In zinc-induced tau toxicity models, NAP prevented tau-mediated microtubule destruction and maintained neuronal viability. NAP treatment also reduced levels of insoluble tau aggregates in the hippocampus of tau-transgenic mice, suggesting direct interference with the tau aggregation cascade. Vulih-Shultzman I. et al. (2007) -- J. Pharmacol. Exp. Ther.

ADNP Syndrome / Helsmoortel-Van der Werf Syndrome

Mutations in the ADNP gene account for approximately 0.17% of autism spectrum disorder cases globally. Hacohen-Kleiman et al. demonstrated that NAP peptide corrects microtubule deficits in ADNP-mutant neurons, restoring dendritic spine morphology and synaptic function. In ADNP-heterozygous mice (modeling the human haploinsufficiency), intranasal NAP improved social behavior, object recognition memory, and reduced repetitive behaviors. Hacohen-Kleiman G. et al. (2018) -- Mol. Psychiatry

Fetal Alcohol Syndrome Protection

NAP protects developing neurons from ethanol toxicity, preventing fetal alcohol spectrum disorder (FASD)-related damage in animal models. Pregnant mice exposed to alcohol and co-treated with NAP produced offspring with significantly fewer learning deficits and reduced neuronal apoptosis compared to alcohol-only controls. This protection is mediated through microtubule stabilization in developing neurons, which are particularly vulnerable to ethanol-induced cytoskeletal disruption. Spong C. Y. et al. (2001) -- J. Pharmacol. Exp. Ther.

Femtomolar Neuroprotection

The defining characteristic of NAP is its extraordinary potency. Bassan et al. demonstrated that NAP protects neurons from diverse toxic insults -- including electrical blockade (tetrodotoxin), beta-amyloid peptide, NMDA excitotoxicity, and oxidative stress (hydrogen peroxide) -- at concentrations as low as 10^-15 M (femtomolar). This represents one of the most potent neuroprotective activities documented for any compound and suggests a catalytic or amplification mechanism rather than simple receptor occupancy. Bassan M. et al. (1999) -- J. Neurochem.

Microtubule stabilization and tau pathology

NAP (davunetide) is an eight-amino-acid fragment (NAPVSIPQ) of activity-dependent neuroprotective protein (ADNP). In preclinical tauopathy models it promotes microtubule stability and reduces tau hyperphosphorylation, providing the rationale for testing in tau-driven neurodegeneration.

• Promotes microtubule assembly and decreases tau phosphorylation in transgenic mouse models
• Showed neuroprotective and cognitive benefits in preclinical Alzheimer's/tauopathy models that did not translate to the PSP clinical endpoint

Clinical neuroprotection (PSP and schizophrenia)

Despite strong preclinical data, intranasal davunetide failed to meet primary endpoints in both a large PSP phase 2/3 trial and a schizophrenia cognition trial. Secondary and re-analysis signals (UPSA functional capacity; possible female-specific PSP benefit) remain hypothesis-generating.

• Negative primary results in the pivotal PSP trial (NCT01110720)
• 2023 re-analysis suggested sex-specific efficacy warranting stratified trial designs